ulocuplumab   Click here for help

GtoPdb Ligand ID: 9161

Synonyms: BMS-936564 | MDX-1338
Immunopharmacology Ligand
Compound class: Antibody
Comment: Ulocuplumab is an IgG4 kappa anti-CXCR4 monoclonal, being developed by Bristol-Myers Squibb as a potential oncolgy therapeutic.
Peptide sequences and structural details for this antibody are available from its IMGT/mAb-DB record.
BLAST sequence analysis of the heavy and light chain peptide sequences of ulocuplumab, reveal identical matches with sequences claimed in patent US8450464 [5]. This identifies clone F7GL as the likely candidate for ulocuplumab.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
Selectivity at GPCRs
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
CXCR4 Primary target of this compound Hs Antibody Binding 8.6 pEC50 - 5
⤷ pEC50 8.6 (EC50 2.26x10-9 M) [5]
Description: Measuring displacement of iodinated SDF-1 from exogenously expressed CXCR4 in vitro.